Vaxil Bio logo

VXL - Vaxil Bio Share Price

C$0.125 0.0  0.0%

Last Trade - 09/04/21

Micro Cap
Market Cap £9.95m
Enterprise Value £9.57m
Revenue £n/a
Position in Universe 1713th / 2707
Unlock VXL Revenue
Relative Strength (%)
1m -2.00%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -83.8%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.000
Balance Sheet
FINANCIAL BRIEF: : For the nine months ended 30 September 2020, VaxilBio Ltd revenues was not reported. Net loss increased 18%to C$783K. Higher net loss reflects General andadministration costs - Balan increase of 91% to C$229K(expense), Office rental and other related expensesincrease from C$9K to C$39K (expense), Depreciationincrease of 75% to C$7K (expense). Basic Earnings per Shareexcluding Extraordinary Items remained flat at -C$0.01.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


VXL Revenue Unlock VXL Revenue

Net Income

VXL Net Income Unlock VXL Revenue

Normalised EPS

VXL Normalised EPS Unlock VXL Revenue

PE Ratio Range

VXL PE Ratio Range Unlock VXL Revenue

Dividend Yield Range

VXL Dividend Yield Range Unlock VXL Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
VXL EPS Forecasts Unlock VXL Revenue
Profile Summary

Vaxil Bio Ltd., formerly Emerge Resources Corp., is an immune-oncology biotechnology company. The Company is engaged in research and development of ImMucin vaccine to treat cancer. The Company develops immunotherapies, including neoantigen peptide products, and antibodies to treat cancer and infectious diseases. The Company offers VaxHit platform, which allows for identification, isolation and production of specific antigen-based immunotherapy products. The Company offers its products from VaxHit technology, which uses the signal peptide (SP) domain in selected targets as core antigens. The Company's product, ImMucin, which has received orphan drug status and designed for the treatment of multiple myeloma (MM) cancer. The Company's ImMucin is in Phase I clinical trial to treat antigen specific immunotherapies; SPmAb2 and SPmAb6 are in pre-clinical stage to treat SP specific antibodies, and MTbuVax is in pre-clinical stage to treat anti-infectives.

Last Annual December 31st, 2019
Last Interim September 30th, 2020
Incorporated October 28, 2009
Public Since March 2, 2011
No. of Shareholders: n/a
No. of Employees: n/a
Sector Healthcare
Industry Biotechnology & Medical Research
Exchange TSX Venture Exchange
Shares in Issue 136,628,973
Free Float (0.0%)
Eligible for
VXL Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for VXL
Upcoming Events for VXL
Frequently Asked Questions for Vaxil Bio
What is the Vaxil Bio share price?

As of 09/04/21, shares in Vaxil Bio are trading at C$0.125, giving the company a market capitalisation of £9.95m. This share price information is delayed by 15 minutes.

How has the Vaxil Bio share price performed this year?

Shares in Vaxil Bio are currently trading at C$0.125 and the price has moved by -27.27% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Vaxil Bio price has moved by -46.76% over the past year.

What are the analyst and broker recommendations for Vaxil Bio?

There are no analysts currently covering Vaxil Bio.

When will Vaxil Bio next release its financial results?

Vaxil Bio is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-09-30
What is the Vaxil Bio dividend yield?

Vaxil Bio does not currently pay a dividend.

Does Vaxil Bio pay a dividend?

Vaxil Bio does not currently pay a dividend.

When does Vaxil Bio next pay dividends?

Vaxil Bio does not currently pay a dividend.

How do I buy Vaxil Bio shares?

To buy shares in Vaxil Bio you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Vaxil Bio?

Shares in Vaxil Bio are currently trading at C$0.125, giving the company a market capitalisation of £9.95m.

Where are Vaxil Bio shares listed? Where are Vaxil Bio shares listed?

Here are the trading details for Vaxil Bio:

Country of listing: Canada
Exchange: CVE
Ticker Symbol: VXL
What kind of share is Vaxil Bio?

Based on an overall assessment of its quality, value and momentum, Vaxil Bio is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Vaxil Bio share price forecast 2021?

We were not able to load any forecast data for Vaxil Bio.

How can I tell whether the Vaxil Bio share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Vaxil Bio. Over the past six months, the relative strength of its shares against the market has been -14.14%. At the current price of C$0.125, shares in Vaxil Bio are trading at -25.18% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Vaxil Bio PE Ratio?

We were not able to find PE ratio data for Vaxil Bio.

Who are the key directors of Vaxil Bio?

Vaxil Bio's management team is headed by:

Isaac Maresky - DRC
Gadi Levin - CFO
Ari Kellen - IND
Shawn Langer - IND
David Goren - CHM
Who are the major shareholders of Vaxil Bio?

Here are the top five shareholders of Vaxil Bio based on the size of their shareholding:

Kellen (Ari S) Individual Investor
Percentage owned: 4.06% (5.54m shares)
Langer (Shawn) Individual Investor
Percentage owned: 3.65% (4.99m shares)
Levin (Gadi) Individual Investor
Percentage owned: 0.48% (657k shares)
Goren (David) Individual Investor
Percentage owned: 0.34% (467k shares)
Similar to VXL
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.